entertainment -WSS

entertainment

author：hotspot 2025-09-29 18:17:32 - browse：3715

The headquarter of Biotechnology company Ionis Pharmaceuticals, consists of glass windows, pale yellow exteriors and plants outside the building — biotech coverage from STAT — courtesy Ionis Pharmaceuticals

Ionis Pharmaceuticals, a California company that pioneered a whole class of RNA-targeted medicines, reported on Friday that a pair of late-stage trials showed that its experimental therapy for hereditary angioedema benefitted patients — including those taking drugs currently on the market.

In one of the Phase 3 trials, dubbed OASIS, patients with hereditary angioedema, a rare disease characterized by severe bouts of swelling, were given injections of donidalorsen either monthly or every two months. Those in the former group had an 81% lower monthly rate of swelling attacks after 25 weeks than patients given a placebo, while the reduction compared to placebo was 55% for those treated every two months.

The other study, OASISplus, found that donidalorsen’s benefits deepened and converged after up to an additional year of treatment, with swelling attack rates dropping by 92% to 93% regardless of how often patients were dosed. Notably, this study also tracked patients who switched over to donidalorsen from existing therapies meant to prevent swelling attacks, including drugs sold by Takeda and BioCryst Pharmaceuticals. Patients who switched to the Ionis drug saw their swelling attack rates drop by 62% compared to previous treatment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： AstraZeneca bets AAV gene therapy will still deliver the goods

WSS

2024 GOP presidential candidates spar over abortion in debate

Psilocybin's anti

Actors' union, Hollywood studios squabble over which side to blame as strike enters 5th day

Lindsay Lohan welcomes 1st child with husband Bader Shammas

Medical experts are missing from AI regulatory conversations

Departing Stanford president retracts two papers

leisure time

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

In age of alternative facts, a scholarly course on calling out crap

Researchers separate signal from noise in heart wearable data

Psychedelics group wrestles with new pharma identity

Australia’s approach to dialysis celebrates life

Cancer drug shortages should be causing more outrage

Ebola public health emergency is over, WHO declares

What does generative AI mean for health care? We asked experts

STAT's 2023 biotech VC rankings: ARCH Venture Partners tops list

After affirmative action ruling, medical educators look to 'holistic review'

Drug firms test therapies to halt Alzheimer’s before symptoms arise

explore

The kidney, in all its complexity, is captured in a new atlas

India sets sights on home

Researchers separate signal from noise in heart wearable data

What do new weight loss drugs mean for bariatric surgery?

Ebola public health emergency is over, WHO declares

Gilgo Beach murders: What questions remain following Rex Heuermann's arrest?

explore

leisure time

focus

hotspot